Recent developments in the pharmaceutical industry underscore the volatile nature of advancements and market dynamics affecting prominent companies. The latest updates reveal a mix of struggles and achievements that highlight how pharmaceutical giants are navigating the complexities of drug
Sterling Pharma Solutions is significantly expanding its GMP antibody-drug conjugate (ADC) manufacturing capacity with a £10 million investment aimed at doubling the current capacity at its Deeside, UK site. This expansion involves commissioning a new 2,300-square-foot suite, which includes a
Global biopharma giant GSK (GlaxoSmithKline) has made a monumental decision to significantly expand its facility in Marietta, Lancaster County, Pennsylvania. The pharmaceutical company is committing up to $800 million to enhance its research, development, and manufacturing capabilities. This
PureTech Health, a Boston-based biotechnology firm, employs an innovative "hub-and-spoke" model, centralizing resources and expertise to support various offshoot companies focused on specific therapeutic areas or drug-making technologies. This approach aims to merge the strengths of a
Sutro Biopharma, Inc. (NASDAQ:STRO) has experienced a dramatic drop in its stock value over the last three years, significantly impacting its shareholders who have seen their investments diminish by 80%. Despite the company's impressive annual revenue growth of 38%, this financial success
Tevogen Bio Holdings Inc. (Nasdaq: TVGN), along with its founding CEO, Dr. Ryan Saadi, has been honored for pioneering efforts in addressing health inequality through innovative medical solutions. The company, recognized by the Warren Township of New Jersey, received a proclamation from Mayor
